Catalyst Pharmaceuticals, Inc. (CPRX) - Stock Analysis
Last updated: Apr 11, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very strong liquidity ⢠High profitability ⢠Low capex/ROIC CPRX is highly cashârich and profitable with negligible leverage, strong margins and FCF but low capex and subdued ROIC suggesting cash is underâdeployed for higher returns.
Price Behavior
Key Price Behavior Insights: ⢠Modest uptrend ⢠Upper-range bias ⢠Moderate volatility Support Level: $23.0â$23.4 (secondary $22.33) Resistance Level: $25.60 Stock is up ~6.6% over the last month, sitting in the upper third of a moderate ~13% range with clear support around $23.0â$23.4 (secondary $22.33) and near-term resistance at $25.60âfailure to clear $25.60 or a break below $23.0 would flip the short-term bias.
Sentiment & News
Key News Insights: ⢠Commercial traction ⢠Value investor interest ⢠Mixed momentum Catalyst (CPRX) is showing commercial momentum with Firdapse and early Agamree traction, attracting value-buy interest and a bullish consensus PT (~45% upside) amid mixed short-term price action.
AI Summary
Catalyst has transformed from a legacy litigation play into a cash-rich, commercially driven rare-disease franchiser where the investment hinge is now whether management can sustain FIRDAPSE cashflows and convert AGAMREE's adoption into durable growth while productively deploying ~$709M in cash (buybacks/M&A) to meaningfully lift ROIC.
Description
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company based in Coral Gables, Florida, that develops and sells therapies for rare neuromuscular and neurological disorders in the United States. Its marketed products include amifampridine formulations for adult and pediatric Lambert-Eaton myasthenic syndrome, and the company is advancing that therapy into additional neuromuscular indications such as certain forms of myasthenia gravis and spinal muscular atrophy. Catalyst also maintains licensing and collaboration arrangements with third parties, including BioMarin and Endo Ventures, and was founded in 2002 (renamed to its current corporate identity in 2015).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | CPRX | Catalyst Pharmaceuticals, Inc. | Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate. | Closed | +1.9% |